Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06082856

Evaluation of the Hemodynamic Effect of Dexmedetomidine in Scheduled Outpatient Surgery: Single-center Prospective Randomized Double-blind Non-inferiority Study

Led by Centre Hospitalier Universitaire de Nīmes · Updated on 2025-06-06

594

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating the effects of two anesthesia drugs, dexmedetomidine and sufentanil, during scheduled outpatient surgeries. The study aims to compare the impact of these drugs on hemodynamic stability, meaning how stable blood pressure and heart rate remain during the induction of general anesthesia. This study focuses on patients undergoing various types of surgeries such as oral, orthopedic, urological, digestive, and gynecological procedures, and addresses concerns related to opiates causing nausea, vomiting, and delayed awakening. Participants will be randomly assigned to receive either dexmedetomidine or sufentanil during the induction of general anesthesia. Dexmedetomidine will be given as a titrated intravenous bolus dose of 0.5 µg/kg up to a maximum of 50 µg over 5 minutes. Sufentanil will be administered intravenously at a dose of 0.25 µg/kg, with a maximum of 20 µg, at anesthetic induction. The study is double-blinded, meaning neither the patients nor the researchers know which treatment is given. The focus is on outpatient surgeries where managing pain and side effects efficiently is important. During the study, participants will be closely monitored for intraoperative hemodynamic stability within 60 minutes after anesthesia induction. Additional assessments include heart rate, blood pressure episodes, vasopressor and atropine use during surgery, and recovery in the intensive care unit on the day of surgery. Patient-reported pain and nausea will be tracked up to seven days after surgery. Researchers will also evaluate the overall success of ambulatory management, patient satisfaction, and any adverse events following surgery. The total duration of participation spans from the day of surgery to seven days post-operation.

CONDITIONS

Brief Title

Evaluation of the Hemodynamic Effect of Dexmedetomidine in Scheduled Outpatient Surgery

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient scheduled for oral, orthopedic, urological, digestive, or gynecological surgery under general anesthesia
  • Patient has given free and informed consent and signed the consent form
  • Patient is a member or beneficiary of a health insurance plan
Not Eligible

You will not qualify if you...

  • Subject currently excluded by participation in a previous study
  • Subject unable to give consent or receive informed information
  • Patient under legal protection such as safeguard of justice or guardianship
  • Known allergy to dexmedetomidine or other drugs
  • Contraindication to general anesthesia or outpatient management
  • Patient treated with beta-blocker, ACE inhibitor, or ARB2
  • Patient with ASA score of 4
  • Heart rate below 50 beats per minute
  • Cardiovascular conditions including coronary insufficiency, obstructive cardiomyopathy, severe hypertension, or ventricular rhythm/conduction disorder
  • Liver insufficiency (prothrombin rate under 70%, liver enzymes or bilirubin three times normal)
  • Kidney insufficiency (clearance under 50 ml/min)
  • Pregnant, giving birth, or nursing patients

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 1 day

Participants receive induction of general anesthesia by administration of either dexmedetomidine or sufentanil during scheduled outpatient surgery.

1 surgical visit on the day of surgery

Post-operative Follow-up

Duration - 7 days

Participants are monitored for recovery, pain, nausea, vomiting, and adverse events following surgery.

Follow-up visits or assessments on Days 0, 1, 2, and 7 after surgery

Trial Site Locations

Total: 1 location

1

CHU de Nîmes

Nîmes, France

Actively Recruiting

Loading map...

Research Team

Y

Yann Gricourt

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Similar Trials

2024 NewAnescat Register

Anesthesia

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here